Digoxin: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 10: | Line 10: | ||
==US Brand Names== | ==US Brand Names== | ||
'''LANOXIN'''<sup>®</sup>, '''DIGOXIN'''<sup>®</sup> | |||
==FDA Package Insert== | ==FDA Package Insert== | ||
Revision as of 23:45, 29 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
For patient information, click here.
Overview
Category
US Brand Names
LANOXIN®, DIGOXIN®
FDA Package Insert
| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages